Neumora Therapeutics, Inc. (NASDAQ:NMRA – Get Free Report)’s stock price reached a new 52-week high on Wednesday after William Blair upgraded the stock from a market perform rating to an outperform rating. The stock traded as high as $3.64 and last traded at $3.54, with a volume of 2286850 shares changing hands. The stock had previously closed at $3.20.
Several other equities research analysts have also issued reports on the stock. Leerink Partners started coverage on shares of Neumora Therapeutics in a research report on Monday, January 12th. They set an “outperform” rating and a $8.00 target price for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Neumora Therapeutics in a report on Thursday, January 22nd. Royal Bank Of Canada raised Neumora Therapeutics from a “sector perform” rating to an “outperform” rating and increased their target price for the company from $4.00 to $7.00 in a research note on Monday, December 1st. Mizuho set a $6.00 price target on Neumora Therapeutics in a research report on Monday, January 5th. Finally, Stifel Nicolaus upped their price objective on Neumora Therapeutics from $2.00 to $3.00 and gave the stock a “hold” rating in a report on Monday, November 17th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has given a Hold rating and three have given a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $8.13.
View Our Latest Stock Report on Neumora Therapeutics
Institutional Inflows and Outflows
Hedge funds have recently made changes to their positions in the company. Siren L.L.C. boosted its position in Neumora Therapeutics by 44.3% during the 4th quarter. Siren L.L.C. now owns 6,288,783 shares of the company’s stock valued at $11,257,000 after buying an additional 1,930,500 shares during the period. Jacobs Levy Equity Management Inc. bought a new stake in shares of Neumora Therapeutics in the third quarter worth about $1,512,000. Millennium Management LLC increased its holdings in Neumora Therapeutics by 63.1% during the 3rd quarter. Millennium Management LLC now owns 2,008,248 shares of the company’s stock valued at $3,655,000 after purchasing an additional 776,856 shares during the period. Marshall Wace LLP bought a new position in Neumora Therapeutics during the 4th quarter valued at approximately $1,045,000. Finally, Goldman Sachs Group Inc. lifted its holdings in Neumora Therapeutics by 127.5% in the 4th quarter. Goldman Sachs Group Inc. now owns 858,502 shares of the company’s stock worth $1,537,000 after buying an additional 481,128 shares during the period. 47.65% of the stock is owned by hedge funds and other institutional investors.
Neumora Therapeutics Trading Up 10.6%
The company has a debt-to-equity ratio of 0.15, a quick ratio of 6.85 and a current ratio of 6.85. The stock has a market capitalization of $591.50 million, a P/E ratio of -2.41 and a beta of 3.20. The stock has a 50-day moving average price of $2.12 and a two-hundred day moving average price of $2.04.
Neumora Therapeutics Company Profile
Neumora Therapeutics, headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing precision therapies for disorders of the central nervous system. The company applies an integrated approach that combines advanced biological insights, single-cell genomics and machine learning to accelerate the discovery and development of novel treatments for neurological and psychiatric diseases.
Neumora’s product pipeline spans small molecules, biologics and gene-based modalities targeting areas of high unmet need such as neurodegenerative conditions, mood and anxiety disorders, neuropathic pain and movement disorders.
Further Reading
- Five stocks we like better than Neumora Therapeutics
- Energy Security Is Now National Security – Positioning Is Happening Now
- 1968. 1980. 2020. Here’s the pattern…
- Your Bank Account Is No Longer Safe
- Trump’s AI Secret: 100X Faster Than Nvidia
- This $15 Stock Could Go Down as the #1 Stock of 2026
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Should You Invest $1,000 in Neumora Therapeutics Right Now?
Before you consider Neumora Therapeutics, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Neumora Therapeutics wasn’t on the list.
While Neumora Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
Click the link to see MarketBeat’s list of seven stocks and why their long-term outlooks are very promising.
